Dataset Information

Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis.

ABSTRACT: UNLABELLED: BACKGROUND: The resistance of endometriotic tissue to progesterone can be explained by alterations in the distribution of progesterone receptor (PR) and estrogen receptor (ER) isoforms. The aims of this study were to examine the expressions of PR-A, PR-B, ER? and ER? in endometrioma and assess whether these expressions are affected by dienogest or leuprolide acetate (LA) treatment. METHODS: We enrolled 60 females, including 43 patients with endometriosis (14 who received no medical treatment, 13 who received dienogest and 16 who received LA before undergoing laparoscopic surgery) and 17 patients with leiomyoma. The expression levels of PR and ER isoforms in eutopic and ectopic endometrium were assayed with quantitative real-time PCR, and confirmed with immunohistochemistry. RESULTS: A decreased PR-B/PR-A ratio and an increased ER?/ER? ratio were demonstrated in ectopic endometrium derived from females with endometriosis compared with the ratios observed in eutopic endometrium obtained from females without endometriosis. Although LA treatment did not affect the PR-B/PR-A and ER?/ER? ratios, dienogest treatment increased the PR-B/PR-A ratio and decreased the ER?/ER? ratio in patients with endometriomas. CONCLUSIONS: Dienogest may improve progesterone resistance in endometriotic tissue by increasing the relative expressions of PR-B and PR-A, and decreasing the relative expressions of ER? and ER?.

SUBMITTER: Hayashi A

PROVIDER: S-EPMC3541078 | biostudies-other | 2012

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis.

Hayashi Atsushi A Tanabe Akiko A Kawabe Sachiko S Hayashi Mika M Yuguchi Hiroko H Yamashita Yoshiki Y Okuda Kiyoji K Ohmichi Masahide M

Journal of ovarian research 20121101 1

<h4>Unlabelled</h4><h4>Background</h4>The resistance of endometriotic tissue to progesterone can be explained by alterations in the distribution of progesterone receptor (PR) and estrogen receptor (ER) isoforms. The aims of this study were to examine the expressions of PR-A, PR-B, ERα and ERβ in endometrioma and assess whether these expressions are affected by dienogest or leuprolide acetate (LA) treatment.<h4>Methods</h4>We enrolled 60 females, including 43 patients with endometriosis (14 who r ...[more]

PMID: 23113924

Similar Datasets

Project description:Expression of the progesterone receptor (PR) has been reported to influence survival outcomes in patients with ovarian high-grade serous carcinoma (HGSC). In the present study, we attempted to investigate the association among PR and its isoforms' expression, platinum sensitivity, and survival in ovarian HGSC. This retrospective study reviewed ovarian HGSC patients who received surgery followed by adjuvant chemotherapy. We analyzed total PR and PR isoform-B (PR-B) expression by immunohistochemical staining and quantified using the H-score. Then, we compared platinum sensitivity and survival outcomes between those patients with weak and strong PR-B expression. Cisplatin viability assays were carried out in ovarian HGSC cell lines (OC-3-VGH and OVCAR-3) with different PR-B expression. Among 90 patients, 49 and 41 patients were considered to have platinum-sensitive and platinum-resistant disease, respectively. Pearson's correlation model showed that the H-score of total PR correlated positively with PR-B (r = 0.813). The PR-B H-score of tumors was significantly higher in the platinum-sensitive group (p = 0.004). Multivariate analysis revealed that the PR-B H-score and optimal debulking status were independent factors predicting platinum sensitivity. When compared with strong PR-B expression, patients with weak PR-B had significantly poorer progression-free (p = 0.021) and cancer-specific survival (p = 0.046). In a cell model, cisplatin-resistant OC-3-VGH cells expressed a lower level of PR-B than wild-type cells. Overexpression of PR-B or progesterone could increase cisplatin sensitivity in both OC-3-VGH and OVCAR-3 cells via the mechanism of promoting cisplatin-related apoptosis. When compared to weak PR-B, ovarian HGSC patients with a strong PR-B expression had a better chance of platinum sensitivity and survival, and this finding was compatible with our experimental results. Progesterone seemed to be a platinum sensitizer, but the value of adding progesterone in the treatment of ovarian HGSC should be further investigated.

Project description:Compelling evidence shows that progestins regulate breast cancer growth. Using preclinical models, we demonstrated that antiprogestins are inhibitory when the level of progesterone receptor isoform A (PR-A) is higher than that of isoform B (PR-B) and that they might stimulate growth when PR-B is predominant. The aims of this study were to investigate ex vivo responses to mifepristone (MFP) in breast carcinomas with different PR isoform ratios and to examine their clinical and molecular characteristics.We performed human breast cancer tissue culture assays (n?=?36) to evaluate the effect of MFP on cell proliferation. PR isoform expression was determined by immunoblotting (n?=?282). Tumors were categorized as PRA-H (PR-A/PR-B ? 1.2) or PRB-H (PR-A/PR-B ? 0.83). RNA was extracted for Ribo-Zero-Seq sequencing to evaluate differentially expressed genes. Subtypes and risk scores were predicted using the PAM50 gene set, the data analyzed using The Cancer Genome Atlas RNA-seq gene analysis and other publicly available gene expression data. Tissue microarrays were performed using paraffin-embedded tissues (PRA-H n?=?53, PRB-H n?=?24), and protein expression analyzed by immunohistochemistry. All statistical tests were two-sided.One hundred sixteen out of 222 (52.3%) PR+ tumors were PRA-H, and 64 (28.8%) PRB-H. Cell proliferation was inhibited by MFP in 19 of 19 tissue cultures from PRA-H tumors. A total of 139 transcripts related to proliferative pathways were differentially expressed in nine PRA-H and seven PRB-H tumors. PRB-H and PRA-H tumors were either luminal B or A phenotypes, respectively ( P = .03). PRB-H cases were associated with shorter relapse-free survival (hazard ratio [HR] = 2.70, 95% confidence interval [CI] = 1.71 to 6.20, P = .02) and distant metastasis-free survival (HR?=?4.17, 95% CI?=?2.18 to 7.97, P?<? .001). PRB-H tumors showed increased tumor size ( P?<? .001), Ki-67 levels ( P?<? .001), human epidermal growth factor receptor 2 expression ( P?=? .04), high grades ( P?=? .03), and decreased total PR ( P?=? .004) compared with PRA-H tumors. MUC-2 ( P?<? .001) and KRT6A ( P?=? .02) were also overexpressed in PRB-H tumors.The PRA/PRB ratio is a prognostic and predictive factor for antiprogestin responsiveness in breast cancer.

Dataset Information

Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis.

Publications

Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure